ES2578729T3 - Agente terapéutico para enfermedades relacionadas con el hígado - Google Patents

Agente terapéutico para enfermedades relacionadas con el hígado Download PDF

Info

Publication number
ES2578729T3
ES2578729T3 ES10812011.4T ES10812011T ES2578729T3 ES 2578729 T3 ES2578729 T3 ES 2578729T3 ES 10812011 T ES10812011 T ES 10812011T ES 2578729 T3 ES2578729 T3 ES 2578729T3
Authority
ES
Spain
Prior art keywords
therapeutic agent
related diseases
liver related
liver
vein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10812011.4T
Other languages
English (en)
Inventor
Akifumi Matsuyama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Osaka Air Machine Service Ltd
Original Assignee
Osaka Air Machine Service Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osaka Air Machine Service Ltd filed Critical Osaka Air Machine Service Ltd
Application granted granted Critical
Publication of ES2578729T3 publication Critical patent/ES2578729T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Un agente terapéutico que comprende células progenitoras multilinaje derivadas de tejido adiposo para su uso en el tratamiento de una enfermedad relacionada con el hígado, donde el agente es para administrar a través de la vena porta, a través de una vena, a través de una arteria, o a través de un conducto biliar.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9

Claims (1)

  1. imagen1
ES10812011.4T 2009-08-28 2010-08-27 Agente terapéutico para enfermedades relacionadas con el hígado Active ES2578729T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009198166 2009-08-28
JP2009198166 2009-08-28
PCT/JP2010/064623 WO2011024962A1 (ja) 2009-08-28 2010-08-27 肝臓関連疾患治療薬

Publications (1)

Publication Number Publication Date
ES2578729T3 true ES2578729T3 (es) 2016-07-29

Family

ID=43628060

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10812011.4T Active ES2578729T3 (es) 2009-08-28 2010-08-27 Agente terapéutico para enfermedades relacionadas con el hígado

Country Status (5)

Country Link
US (1) US8784803B2 (es)
EP (1) EP2471542B1 (es)
JP (1) JP4965000B2 (es)
ES (1) ES2578729T3 (es)
WO (1) WO2011024962A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2554176B1 (en) * 2011-08-04 2016-07-27 ETHIANUM Betriebsgesellschaft mbH & Co. KG Means for liver regeneration
US9533013B2 (en) * 2013-03-13 2017-01-03 University Of North Carolina At Chapel Hill Method of treating pancreatic and liver conditions by endoscopic-mediated (or laparoscopic-mediated) transplantation of stem cells into/onto bile duct walls of particular regions of the biliary tree
WO2016167977A1 (en) 2015-04-14 2016-10-20 Mayo Foundation For Medical Education And Research Methods and materials for delivering agents to liver tissue
JP6923137B2 (ja) * 2018-06-15 2021-08-18 有限会社大阪空気機械サービス 組織治癒剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE286118T1 (de) * 1998-03-13 2005-01-15 Osiris Therapeutics Inc Anwendungen für humane nicht autologe, mesenchymale stammzellen
US20030082152A1 (en) * 1999-03-10 2003-05-01 Hedrick Marc H. Adipose-derived stem cells and lattices
US20030161816A1 (en) * 2001-12-07 2003-08-28 Fraser John K. Systems and methods for treating patients with processed lipoaspirate cells
ES2257225B1 (es) * 2006-02-17 2007-03-16 Grifols, S.A Preparacion terapeutica de fviia de muy alta pureza y metodo para su obtencion.
RU2008146395A (ru) 2006-04-25 2010-05-27 Борд Ов Супервайзорс Ов Луизиана Стейт Юниверсити Энд Агрикалчарал Энд Микэникал Колледж (Us) Стволовые клетки жировой ткани взрослого человека в регенерации печени
ES2439942T3 (es) 2006-08-03 2014-01-27 Smart Packaging Solutions (Sps) Documento securizado, especialmente pasaporte electrónico con seguridad reforzada
JPWO2008153180A1 (ja) 2007-06-14 2010-08-26 財団法人先端医療振興財団 脂肪組織由来細胞から肝小葉様細胞塊を得る方法
JP5338322B2 (ja) 2008-01-11 2013-11-13 ダイキン工業株式会社 空気調和装置の室内ユニット

Also Published As

Publication number Publication date
JP4965000B2 (ja) 2012-07-04
JPWO2011024962A1 (ja) 2013-01-31
EP2471542B1 (en) 2016-04-27
EP2471542A1 (en) 2012-07-04
EP2471542A4 (en) 2013-11-20
WO2011024962A1 (ja) 2011-03-03
US20120156181A1 (en) 2012-06-21
US8784803B2 (en) 2014-07-22

Similar Documents

Publication Publication Date Title
TN2021000028A1 (en) Methods of reducing the need for peripheral arterial revascularization in a statin-treated subject
SV2011003939A (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
PE20181139A1 (es) Composiciones y metodos para inhibir la expresion genica de lpa
CR11749A (es) Tratamiento de la disnea asociada con insuficiencia cardiaca aguda con relaxina
CL2012002037A1 (es) Uso de agonista doble del glucagon-glp-1 como agente inotropico en el tratamiento de la cardiopatía o la disfuncion cardiaca
UA99152C2 (ru) Восстановление и регенерация почечной ткани с использованием клеток, полученных с человеческой ткани пупочного канатика
ES2422739T3 (es) Composición para el diagnóstico, prevención o tratamiento de enfermedades relacionadas con células que expresan IL-8 o GRO-, que comprende MSC de UCB
NI200800169A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento del dolor
NZ618734A (en) Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
EA201300121A1 (ru) Ингибитор дпп-4 в комбинации с дополнительным противодиабетическим агентом, таблетки, включающие указанные композиции, их применение и способ их получения
EA201100358A1 (ru) Дабигатран для чрескожной хирургической катетеризации сердца
PA8794401A1 (es) Acidos 6-fenilnicotinicos sustituidos y su uso
CL2012001961A1 (es) Método para tratar una enfermedad o trastorno en que aumentan los niveles de hormonas de estrés y/o disminuyen los niveles de hormonas de andrógenos, en que se administra un compuesto pirrolo-[1,2-c]-imidazol-bencil sustituido; su uso en insuficiencia cardíaca, entre otros; y compuestos pirrolo-[1,2-c]-imidazol-bencil sustituidos.
ES2578729T3 (es) Agente terapéutico para enfermedades relacionadas con el hígado
CL2011000099A1 (es) Uso de una beta-defensina humana en la manufactura de un medicamento que sirve para el tratamiento de una enfermedad intestinal inflamatoria.
PE20181332A1 (es) Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos
WO2009004995A1 (ja) 生理活性物質を定着および発現させる方法
ES2552654T3 (es) Uso de LCAT para tratar la anemia y la disfunción de los glóbulos rojos
BR112014003071A2 (pt) tratamento de doença vascular periférica com o uso de células derivadas do tecido do cordão umbilical
BR112012017994B8 (pt) composição líquida, uso de uma composição líquida, e, métodos para preparar uma composição líquida e para tratamento de um distúrbio
BR112014020271A8 (pt) Composição farmacêutica e métodos para diminuir a frequência de micção em paciente
BR112013000613A2 (pt) composições secas e dispositivos que contêm tais composições secas
AR084216A1 (es) Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit
RU2012131164A (ru) (метилсульфонил)этил-бензол-изоиндолиновые производные и их терапевтическое применение
AR103415A1 (es) Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2